Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · Real-Time Price · USD
1.260
-0.140 (-10.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Anebulo Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 |
| Selling, General & Admin | 4.25 | 4.76 | 6.18 | 3.87 | 1.34 | 0.14 |
| Research & Development | 3.75 | 3.55 | 5.6 | 2.96 | 2.27 | 0.9 |
| Operating Expenses | 8 | 8.31 | 11.78 | 6.83 | 3.61 | 1.04 |
| Operating Income | -8 | -8.31 | -11.78 | -6.83 | -3.61 | -1.04 |
| Interest Expense | -0.24 | -0.15 | - | - | -0.01 | -0.01 |
| Interest & Investment Income | 0.15 | 0.25 | 0.09 | 0.01 | 0 | - |
| Other Non Operating Income (Expenses) | 0.43 | 0.01 | -0.04 | -0 | -26.63 | - |
| Pretax Income | -7.67 | -8.2 | -11.73 | -6.83 | -30.25 | -1.05 |
| Net Income | -7.67 | -8.2 | -11.73 | -6.83 | -30.25 | -1.05 |
| Preferred Dividends & Other Adjustments | - | - | - | - | 8.21 | - |
| Net Income to Common | -7.67 | -8.2 | -11.73 | -6.83 | -38.46 | -1.05 |
| Shares Outstanding (Basic) | 26 | 26 | 25 | 23 | 14 | 12 |
| Shares Outstanding (Diluted) | 26 | 26 | 25 | 23 | 14 | 12 |
| Shares Change (YoY) | 2.48% | 2.98% | 7.41% | 71.49% | 13.44% | - |
| EPS (Basic) | -0.29 | -0.32 | -0.47 | -0.29 | -2.83 | -0.09 |
| EPS (Diluted) | -0.29 | -0.32 | -0.47 | -0.29 | -2.83 | -0.09 |
| Free Cash Flow | -6.65 | -8.09 | -9.68 | -5.44 | -4.87 | -0.9 |
| Free Cash Flow Per Share | -0.25 | -0.31 | -0.39 | -0.23 | -0.36 | -0.08 |
| EBIT | -8 | -8.31 | -11.78 | -6.83 | -3.61 | -1.04 |
Source: S&P Capital IQ. Standard template.
Financial Sources.